Last reviewed · How we verify

Lacosamide oral — Competitive Intelligence Brief

Lacosamide oral (Lacosamide oral) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

discontinued Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Lacosamide oral (Lacosamide oral) — UCB Biopharma SRL. 12.1 Mechanism of Action The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lacosamide oral TARGET Lacosamide oral UCB Biopharma SRL discontinued

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lacosamide oral — Competitive Intelligence Brief. https://druglandscape.com/ci/lacosamide-oral. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: